15:13:17 Europe / Stockholm

Kurs & Likviditet

Kursutveckling och likviditet under dagen för detta pressmeddelande

Beskrivning

LandNorge
ListaMERK Equities
SektorHälsovård
IndustriMedicinteknik
SoftOx Solutions är ett norskt medicintekniskt bolag. Bolaget har utvecklat en egenpatenterad lösning baserad på ättiksyra för behandling av kroniska sår hos patienter. Lösningen används för att eliminera infektioner i samband med biofilmer, vilket består av olika kluster av bakterier. En del av läkemedelsutvecklingen sker i samarbete med övriga forskningsinstitut. SoftOx Solutions etablerades under 2012 och har sitt huvudkontor i Oslo.

Kalender

2022-02-15 Bokslutskommuniké 2021
2021-11-17 Kvartalsrapport 2021-Q3
2021-09-08 Kvartalsrapport 2021-Q2
2021-04-29 Kvartalsrapport 2021-Q1
2021-04-14 Ordinarie utdelning SOFTX 0.00 NOK
2021-04-13 Årsstämma 2021
2021-02-09 Bokslutskommuniké 2020
2021-01-04 Extra Bolagsstämma 2021
2020-12-14 Kvartalsrapport 2020-Q3
2020-09-30 Kvartalsrapport 2020-Q2
2020-07-01 Ordinarie utdelning SOFTX 0.00 NOK
2020-06-30 Årsstämma 2020
2020-06-30 Kvartalsrapport 2020-Q1
2020-03-31 Bokslutskommuniké 2019
2019-12-31 Kvartalsrapport 2019-Q3
2019-12-20 Extra Bolagsstämma 2019
2019-09-30 Kvartalsrapport 2019-Q2
2019-06-30 Kvartalsrapport 2019-Q1
2019-06-27 Årsstämma 2019
2019-06-03 Ordinarie utdelning SOFTX 0.00 NOK
2019-03-31 Bokslutskommuniké 2018
2018-12-31 Kvartalsrapport 2018-Q3
2018-08-27 Kvartalsrapport 2018-Q2
2018-07-02 Split SOFTX 1:50
2018-06-07 Kvartalsrapport 2018-Q1
2021-06-07 07:00:00
SoftOx Solutions AS (SoftOx) aims to develop an inhalation solution (SIS) for
the treatment of respiratory tract infections. This has the potential to be a
breakthrough in the future treatment of respiratory infections, including
viruses, bacteria and fungal infections.

"After an intensive research phase, we are very satisfied that the Danish
Medicines Agency (DKMA) considers our documentation positively and has given a
conditional approval to be able to start the study", says Medical Director Glenn
Gundersen. "The conditions that have been communicated are related to additional
safety data and the company is already working on completing the data as
requested. The data will be provided in due time and we believe that the study
can be initiated during the autumn."

For further information, please contact:

Geir Almås, CEO of SoftOx Solutions AS, or
Glenn Gundersen, Medical Director in SoftOx Solutions AS
Mail: ir@soft-ox.com
Phone: Front Desk: (+47) 948-59-599

About SoftOx Solutions AS
SoftOx Solutions AS is a Norwegian BioTech company listed on Euronext Growth
Oslo. Our Vison is "Helping the world fighting infections - developing new ways
of eradicating infections and fighting antimicrobial resistance". We are working
to combat major threats to human health, namely the emergence of antimicrobial
resistance (AMR), biofilm infections in chronic wounds and the spread of
viruses. For more information on SoftOx, visit www.soft-ox.com.